Wyeth Raises 2007 Earnings Guidance, Buoyed By Biologics Revenues
This article was originally published in The Pink Sheet Daily
Executive Summary
Growth is led by 27 percent increase in revenue from biologics compared to the second quarter of 2006.
You may also be interested in...
Wyeth Prevnar 13 Filing Targeted For 2009
Pneumococcal vaccine could provide broadest coverage available and generate peak sales of $4.5 billion in adults and children, exec says.
Wyeth Prevnar 13 Filing Targeted For 2009
Pneumococcal vaccine could provide broadest coverage available and generate peak sales of $4.5 billion in adults and children, exec says.
Barr Seasonique DTC Campaign Producing Results, Firm Says
Direct-to-consumer ads launched in July are driving consumer inquiries to physicians.